In the same year, Kieran et al. [164] published the evaluation of cediranib (AZD2171), an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor [165], in children and adolescents less than 22 years of age with recurrent or refractory primary CNS tumors. This evidence concerns the gene VEGFA and central nervous system neoplasm.